<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>All About MS &#187; progression</title>
	<atom:link href="http://allaboutms.ca/tag/progression/feed/" rel="self" type="application/rss+xml" />
	<link>http://allaboutms.ca</link>
	<description>MS Information and Research</description>
	<lastBuildDate>Tue, 07 Sep 2010 14:11:49 +0000</lastBuildDate>
	<generator>http://wordpress.org/?v=2.9.2</generator>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
			<item>
		<title>Clinical Benefit Of Multiple Sclerosis Drug Discovered</title>
		<link>http://allaboutms.ca/2010/04/15/clinical-benefit-of-multiple-sclerosis-drug-discovered/</link>
		<comments>http://allaboutms.ca/2010/04/15/clinical-benefit-of-multiple-sclerosis-drug-discovered/#comments</comments>
		<pubDate>Thu, 15 Apr 2010 22:07:57 +0000</pubDate>
		<dc:creator>Bonnie</dc:creator>
				<category><![CDATA[MS]]></category>
		<category><![CDATA[Research]]></category>
		<category><![CDATA[multiple sclerosis]]></category>
		<category><![CDATA[progression]]></category>
		<category><![CDATA[relapses]]></category>
		<category><![CDATA[relapsin remitting multiple sclerosis]]></category>

		<guid isPermaLink="false">http://allaboutms.ca/?p=1116</guid>
		<description><![CDATA[A drug whose clinical benefit in treating multiple sclerosis was discovered at Rush University Medical Center was approved by the Food and Drug Administration on January 22 and is now available in the U.S.
The drug, called dalfampridine, is the first therapy for multiple sclerosis that can be taken orally. It is also the first FDA-approved [...]]]></description>
		<wfw:commentRss>http://allaboutms.ca/2010/04/15/clinical-benefit-of-multiple-sclerosis-drug-discovered/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>BHT-3009 &#8211; Program Overview</title>
		<link>http://allaboutms.ca/2009/03/20/bht-3009-program-overview/</link>
		<comments>http://allaboutms.ca/2009/03/20/bht-3009-program-overview/#comments</comments>
		<pubDate>Fri, 20 Mar 2009 06:39:39 +0000</pubDate>
		<dc:creator>Bonnie</dc:creator>
				<category><![CDATA[MS]]></category>
		<category><![CDATA[Avonex]]></category>
		<category><![CDATA[Betaseron]]></category>
		<category><![CDATA[BHT-3009]]></category>
		<category><![CDATA[Copaxone]]></category>
		<category><![CDATA[Depression]]></category>
		<category><![CDATA[MRI]]></category>
		<category><![CDATA[multiple sclerosis]]></category>
		<category><![CDATA[Novatrone]]></category>
		<category><![CDATA[placebo]]></category>
		<category><![CDATA[Primary Progressive MS]]></category>
		<category><![CDATA[progression]]></category>
		<category><![CDATA[Rebif]]></category>
		<category><![CDATA[relapses]]></category>
		<category><![CDATA[relapsin remitting multiple sclerosis]]></category>
		<category><![CDATA[rrms]]></category>
		<category><![CDATA[treatment]]></category>
		<category><![CDATA[tysabri]]></category>

		<guid isPermaLink="false">http://allaboutms.ca/?p=1067</guid>
		<description><![CDATA[Clinical data suggests that Bayhill’s lead product candidate BHT-3009 induces the immune system to tolerize to, rather than attack, the MBP in the myelin sheath. BHT-3009 is a plasmid encoding MBP directed specifically at reprogramming ]]></description>
		<wfw:commentRss>http://allaboutms.ca/2009/03/20/bht-3009-program-overview/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
